Various anti-IL-1β-targeted drugs have been manufactured, including IL-1 receptor antagonists (anakinra), a recombinant human interleukin receptor antagonist that inhibits both IL-1α and IL-1β, but whose usage is unpractical in chronic diseases due to the administration form; monoclonal antibodies (canakinumab) that selectively inhibit IL-1β, whose efficiency in acute myocardial infarction was shown in the CANTOS trial by inducing a 15% reduction of primary clinical events, but with a higher incidence of fatal infections; and IL-1 vaccine. Here, IL1A is linked to myocardial infarction.